Top-News

CAC 40 Index

Index
WKN:  969400 ISIN:  FR0003500008
8.125,96
-0,16%
-13,2514
14:41:21 Uhr
Depot/Watchlist
Weiter abwärts? Short handeln - Jetzt mit Hebel 7,86: MJ1W69
Werbung

Ad-hocs

30.04.25 - GlobeNewswire
ArcelorMittal S.A.: ArcelorMittal reports first quarter 2025
Luxembourg, April 30 , 20 25 - ArcelorMittal (referred to as “ArcelorMittal” or the “Company” or the "Group") (MT (New York, Amsterdam, Paris, Luxembourg), MTS (Madrid)), the world’s ...
24.04.25 - GlobeNewswire
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales ...
18.04.25 - GlobeNewswire
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent ...
17.04.25 - GlobeNewswire
ArcelorMittal announces the publication of its first quarter 2025 sell-side analyst consensus figures
17 April 2025, 19:00 CET
17.04.25 - GlobeNewswire
First quarter 2025 sales
Solid in the Storm Like-​for-like growth of +3.5%
17.04.25 - GlobeNewswire
ArcelorMittal publishes its 2024 Sustainability Report
17 April 2025, 08:30 CET
17.04.25 - GlobeNewswire
Capgemini acquires Delta Capita Group Limited’s subsidiary in the Netherlands to expand its Financial Crime Compliance services footprint in Europe
Media relations: Sam Connatty Tel.: +44 (0)370 904 3601 sam.connatty@capgemini.com Investor relations: Vincent Biraud Tel.: +33 1 47 54 50 87 vincent.biraud@capgemini.com ...
15.04.25 - GlobeNewswire
Publicis Groupe : First Quarter 2025 Revenue
Very strong Q1 at +4.9%
15.04.25 - GlobeNewswire
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous ...
08.04.25 - GlobeNewswire
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in ...
07.04.25 - GlobeNewswire
Availability of the explanatory documentation for the Combined General Meeting of April 29, 2025
Paris, April 7, 2025 Press release Availability of the explanatory documentation for the Combined General Meeting of April 29, 2025 The Combined General Meeting of shareholders ...
07.04.25 - GlobeNewswire
ArcelorMittal announces the commencement of a new share buyback program over the period 2025-2030
7 April 2025, 08:30 CET
04.04.25 - GlobeNewswire
ArcelorMittal announces updated financial calendar for 2025
4 April 2025, 18:00 CET
04.04.25 - GlobeNewswire
ArcelorMittal publishes convening notice for its Annual General Meeting of shareholders
4 April 2025, 08:00 CET
03.04.25 - GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-...
02.04.25 - GlobeNewswire
ArcelorMittal announces the completion of its 85 million shares buyback program
2 April 2025, 10:30 CET
01.04.25 - GlobeNewswire
Share buyback program
L'Oréal announced to have today entered into a mandate with an investment services provider for the purchase of its own shares, under the authorisation approved by the Annual ...
28.03.25 - GlobeNewswire
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-​lowering therapy in hemophilia, offers ...
28.03.25 - GlobeNewswire
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-​ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal ...
27.03.25 - GlobeNewswire
ArcelorMittal announces publication of the 2024 statutory financial statements of ArcelorMittal parent company
27 March 2025, 17:45 CET

Newssuche

Videos

newspaper
12.12.25 -1,72%
Technical Trading: Neues Allzeithoch im Visier
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »